BBS-Bioactive Bone Substitutes Plc | Company Release | May 07, 2024 at 19:00:00 EEST

BBS-Bioactive Bone Substitutes Plc: Annual General Meeting in 2024

Due to scheduling reasons and contrary to the previous announcements (Company announcement, 17 April 2024 at 5:30 p.m., Company announcement, 3 April 2024 at 9:00 a.m. and Company announcement, 27 December 2023 at 5:00 p.m.), the Annual General Meeting of BBS-Bioactive Bone Substitutes Plc is planned to be held on Thursday 13 June 2024 at 2:00 p.m. Company’s Board of Directors will convene the meeting at a later date.

For more information, please contact:
Juliusz Rakowski, CEO
+358 50 448 5132
juliusz.rakowski@bbs-artebone.fi

Certified Advisor:
Nordic Certified Adviser AB,
+46 70 551 67 29,
info@certifiedadviser.se

Distribution
Nasdaq Helsinki
https://www.bbs-artebone.fi/

BBS in brief
BBS -Bioactive Bone Substitutes Plc is an orthobiology company that started its operations in 2003. We have developed a new product for the treatment of complex bone fractures and bone healing issues. Our goal is to provide next-generation medical products for the treatment of bone injuries in orthopedic surgery. In the pharmaceutical industry, the development and research work require perseverance and courage to innovate. We have a track record of over 20 years in this field. Our company is characterized by expertise, innovation, and dedicated employees who are passionate about their work. Our first developed product, ARTEBONE® Paste, is in the final stages of the CE marking process to enable its commercialization in the EU market. We are based in Oulu with a medical manufacturing facility in Reisjärvi, holding a manufacturing license. The company's headquarters are in Oulu, and we employ over 20 people.

BBS has been listed on Nasdaq First North Growth Market Finland since February 2018.

More information: www.bbs-artebone.fi

Attachments
BBS-Bioactive Bone Substitutes Plc: Annual General Meeting in 2024

© Modular Finance, source Nordic Press Releases